Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 18;5:41. doi: 10.1038/s41541-020-0190-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Early development research grade lots (not optimized yet) of the virosomal vaccine MYM-V202 under nasal and oral powder, and sublingual (SL) tablets were reconstituted in water and were administered subcutaneously to rats at day 1 and day 28 to determine if excipients of each new solid dosage form were affecting the antibody response. Each final serum at day 42 was analyzed by the Imperacer assays developed during MACIVIVA project, as illustrated in (a). Data of each animal is shown for better appreciating of the inter-individual variation often observed with suboptimal formulations. Approximate net serum (pre-immune deducted) anti-rgp41 antibody concentrations detected at day 42 (b), and anti-P1 antibody concentrations detected at day 42 (c). Data are from a representative Imperacer assay experiment.